← FDA DRUG APPROVALS

FDA ANDA · ANDA205761

RABEPRAZOLE SODIUM

Sponsor: QUAGEN

APPLICATION
ANDA205761
TYPE
ANDA
ORIGINAL APPROVAL
2017-02-17
LATEST ACTION
2023-10-31
ROUTE
ORAL
DOSAGE FORM
TABLET, DELAYED RELEASE
MARKETING STATUS
Prescription

Products

RABEPRAZOLE SODIUMPrescription
RABEPRAZOLE SODIUM 20MG · TABLET, DELAYED RELEASE · ORAL

Approval history

2023-10-31Labeling · Supplement 11 · standardAP
2022-09-14Labeling · Supplement 7 · standardAP
2021-08-30Labeling · Supplement 6 · standardAP
2019-02-01Labeling · Supplement 2 · standardAP
2019-02-01Labeling · Supplement 3 · standardAP
2017-02-17UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →